Navigation Links
Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire
Date:8/26/2014

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering.

Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.

The analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.

The report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug.

According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis.

Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Route of Administration

08. Market Segmentation by Dosage Form

09. Market Assessment of Valcyte

10. Rate of Incidence and Prevalence

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

20. Key Vendor Analysis

21. Other Reports in this Series

Companies Mentioned:

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Hospira
  • Shire
  • Auritec Pharmaceuticals
  • Chimerix Pharmaceuticals
  • Isis Pharmaceuticals
  • pSivida
  • Sanofi

For more information visit http://www.researchandmarkets.com/research/sp3krb/global

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis
2. MNX Global Logistics renews multi-year contract with NuVasive, Inc.
3. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
4. Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference
5. Cardiomyopathy Global Clinical Trials Review, H2, 2014
6. Vascular Dementias Global Clinical Trials Review, H2, 2014
7. Vocal Cord Paralysis Global Clinical Trials Review, H2, 2014
8. Traumatic Pain Global Clinical Trials Review, H2, 2014
9. Traumatic Spinal Cord Injury Global Clinical Trials Review, H2, 2014
10. Tremor Global Clinical Trials Review, H2, 2014
11. Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):